AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer
← catalyst calendarNCT07617337 · readout in 1,473 d
Sponsored by Chugai Pharmaceutical (industry) · 4519.T — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
102estimated
Sites
5
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-24 | actual | When the study began enrolling |
| Primary completion | 2030-08-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- ALK Positive Non-small Cell Lung Cancer
Interventions
- Drug: AQUA07
- Drug: Lorlatinib
Primary outcomes
what the primary-completion date above is the date OFAdverse events [PartA,B]
measured From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 48 months)
Dose-Limiting Toxicities (DLTs) [PartA,B]
measured From cycle 0 day1 (if applicable) or cycle 1 day 1 to cycle 1 day 21 (each cycle is 21 days)
Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and Recommendation Dose (RD) Determination [PartA,B]
measured From cycle 0 day1 (if applicable) or cycle 1 day 1 to cycle 1 day 21 (each cycle is 21 days)
Permalink · 4519.T's whole pipeline · Catalyst calendar · Every registered study · What changed